Boston Scientific Financial Statements (BSX)
|
|
|
|
Report date
|
|
|
20.02.2024 |
21.02.2024 |
01.05.2024 |
01.08.2024 |
01.11.2024 |
|
01.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
3 725 |
3 725 |
3 856 |
4 120 |
4 209 |
|
15 910 |
|
Operating Income, bln rub |
|
|
584.0 |
584.0 |
693.0 |
747.0 |
733.0 |
|
2 757 |
|
EBITDA, bln rub |
? |
|
1 016 |
883.0 |
984.0 |
812.0 |
1 058 |
|
3 737 |
|
Net profit, bln rub |
? |
|
505.0 |
505.0 |
492.0 |
324.0 |
468.0 |
|
1 789 |
|
|
OCF, bln rub |
? |
|
957.0 |
957.0 |
164.0 |
813.0 |
-1 142 847 |
|
-1 140 913 |
|
CAPEX, bln rub |
? |
|
267.0 |
267.0 |
245.0 |
155.0 |
392.0 |
|
1 059 |
|
FCF, bln rub |
? |
|
690.0 |
690.0 |
-81.0 |
658.0 |
-1 143 239 |
|
-1 141 972 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
23.0 |
|
23.0 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
4.91% |
|
1.29% |
|
|
OPEX, bln rub |
|
|
1 961 |
1 961 |
1 954 |
1 838 |
1 969 |
|
7 722 |
|
Cost of production, bln rub |
|
|
1 147 |
1 147 |
1 209 |
1 535 |
1 561 |
|
5 452 |
|
R&D, bln rub |
|
|
363.0 |
363.0 |
366.0 |
383.0 |
407.0 |
|
1 519 |
|
Interest expenses, bln rub |
|
|
65.0 |
65.0 |
69.0 |
77.0 |
79.0 |
|
290.0 |
|
|
Assets, bln rub |
|
|
35 136 |
35 136 |
36 669 |
37 108 |
38 078 |
|
38 078 |
|
Net Assets, bln rub |
? |
|
19 281 |
19 281 |
19 925 |
20 371 |
20 708 |
|
20 708 |
|
Debt, bln rub |
|
|
9 492 |
9 492 |
11 001 |
10 936 |
11 258 |
|
11 258 |
|
Cash, bln rub |
|
|
865.0 |
865.0 |
2 329 |
2 988 |
2 502 |
|
2 502 |
|
Net debt, bln rub |
|
|
8 627 |
8 627 |
8 672 |
7 948 |
8 756 |
|
8 756 |
|
|
Ordinary share price, rub |
|
|
57.8 |
57.8 |
68.5 |
77.0 |
83.8 |
|
52.5 |
|
Number of ordinary shares, mln |
|
|
1 465 |
1 465 |
1 468 |
1 471 |
1 473 |
|
1 473 |
|
|
Market cap, bln rub |
|
|
84 709 |
84 709 |
100 571 |
113 251 |
123 412 |
|
77 346 |
|
EV, bln rub |
? |
|
93 336 |
93 336 |
109 243 |
121 199 |
132 168 |
|
86 102 |
|
Book value, bln rub |
|
|
-1 109 |
-1 109 |
-273 |
557 |
-79 |
|
-79 |
|
|
EPS, rub |
? |
|
0.34 |
0.34 |
0.34 |
0.22 |
0.32 |
|
1.21 |
|
FCF/share, rub |
|
|
0.47 |
0.47 |
-0.06 |
0.45 |
-776.3 |
|
-775.4 |
|
BV/share, rub |
|
|
-0.76 |
-0.76 |
-0.19 |
0.38 |
-0.05 |
|
-0.05 |
|
|
EBITDA margin, % |
? |
|
27.3% |
23.7% |
25.5% |
19.7% |
25.1% |
|
23.5% |
|
Net margin, % |
? |
|
13.6% |
13.6% |
12.8% |
7.86% |
11.1% |
|
11.2% |
|
FCF yield, % |
? |
|
2.01% |
2.01% |
1.54% |
1.55% |
-925.3% |
|
-1 476% |
|
ROE, % |
? |
|
8.26% |
8.26% |
8.89% |
8.96% |
8.64% |
|
8.64% |
|
ROA, % |
? |
|
4.53% |
4.53% |
4.83% |
4.92% |
4.70% |
|
4.70% |
|
|
P/E |
? |
|
53.2 |
53.2 |
56.8 |
62.1 |
69.0 |
|
43.2 |
|
P/FCF |
|
|
49.7 |
49.7 |
64.8 |
64.4 |
-0.11 |
|
-0.07 |
|
P/S |
? |
|
5.95 |
5.95 |
6.84 |
7.44 |
7.76 |
|
4.86 |
|
P/BV |
? |
|
-76.4 |
-76.4 |
-368.4 |
203.3 |
-1 562 |
|
-979.1 |
|
EV/EBITDA |
? |
|
27.8 |
27.4 |
30.0 |
33.2 |
35.4 |
|
23.0 |
|
Debt/EBITDA |
|
|
2.57 |
2.54 |
2.38 |
2.17 |
2.34 |
|
2.34 |
|
|
R&D/CAPEX, % |
|
|
136.0% |
136.0% |
149.4% |
247.1% |
103.8% |
|
143.4% |
|
|
CAPEX/Revenue, % |
|
|
7.17% |
7.17% |
6.35% |
3.76% |
9.31% |
|
6.66% |
|
| Boston Scientific shareholders |
